Valneva's Stock Rises 3.8% Midday Thursday, Boosted by Bullish VLA15 Profile

Market Dynamics and Technical Analysis

After peaking at around 4.30 euros at the end of November following the announcement of positive Phase 2 results for its VLA15 Lyme disease vaccine candidate, the stock began to consolidate. The decline observed in the previous days seemed natural after a surge of more than 120% over a year recorded at the end of November. Thursday's movement occurs in a favorable technical context: the price is trading slightly below its 50-day moving average positioned at 4.08 euros, but remains well above the 200-day moving average established at 3.45 euros, confirming a bullish underlying trend. The technical support identified at 3.66 euros held during this correction phase, indicating persistent investor interest. Resistance is now at 4.30 euros, a level corresponding to the late November highs. Goldman Sachs adjusted its price target on November 28 from 3.50 to 3.25 euros while maintaining a neutral recommendation, reflecting short-term caution after the strong progression recorded. However, the consensus among analysts remains constructive with an average target of 6.35 euros according to available market data, representing a potential upside of more than 64% from the current price.

Focus on VLA15, a Promising Lyme Disease Vaccine

Interest in Valneva is focused on VLA15, a Lyme disease vaccine candidate developed in partnership with Pfizer. VLA15 is currently the only active vaccine program in clinical development against Lyme disease, and Pfizer plans to submit a marketing authorization application to the FDA and the European Medicines Agency in 2026, subject to positive Phase 3 data. The Phase 3 VALOR trial is expected to conclude by the end of 2025, paving the way for potential commercialization in 2026 or 2027. This timeline largely explains the rebound observed this Thursday: investors are anticipating the final Phase 3 data expected in the coming months. Lyme disease affects approximately 476,000 people annually in the United States and 130,000 in Europe, representing a potential market worth several hundred million euros. Analysts, including Stifel who had estimated an 80% probability of Phase 3 success, consider this program as one of the most attractive risk-reward catalysts in the European biotech sector for the next six months. The current configuration of the stock, with an RSI at 51 in the neutral zone and a MACD close to balance, suggests that a resumption of bullish momentum is conceivable in the short term.

Operational Context Remains Mixed for the Franco-Austrian Lab

The operational context remains nevertheless mixed for the Franco-Austrian laboratory. The company posted revenue of 127 million euros over nine months, up 8.9%, but in an environment marked by the FDA's suspension in November of the license for IXCHIQ, its chikungunya vaccine. This suspension led Valneva to revise its annual sales targets downward, now expected between 155 and 170 million euros compared to a previous range of 170 to 180 million euros. The adjusted EBITDA remains negative at -37.7 million euros over nine months. To enhance its operational efficiency, Valneva announced at the end of November the closure of its historic site in Nantes-Saint-Herblain and the transfer of all its French activities to Lyon, where the new headquarters will be established, while R&D will be centralized in Vienna, Austria. This rationalization aims to optimize costs in a sector where expense control is crucial. From a technical perspective, the MACD indicator displays a balanced histogram at 0.00, indicating short-term indecision, while the high volatility at 13.82 over a month remains characteristic of biotech stocks. The net short position representing about 0.60% of the capital signals persistent caution from certain players, but risk appetite could strengthen as decisive Phase 3 results approach.